Square Pharmaceuticals PLC. (DSE:SQURPHARMA)
Bangladesh · Delayed Price · Currency is BDT 217.60
+0.60 (0.28%)
At close: Sep 3, 2026
DSE:SQURPHARMA Ratios and Metrics
Market cap in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 192,892 | 185,180 | 186,953 | 185,977 | 192,094 | 191,030 | |
Market Cap Growth | -2.86% | -0.95% | 0.52% | -3.18% | 0.56% | 31.17% |
Enterprise Value | 120,683 | 126,115 | 130,781 | 132,967 | 141,464 | 147,209 |
Last Close Price | 217.60 | 197.14 | 189.15 | 178.84 | 176.04 | 170.40 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | 7.46 | 7.73 | 8.93 | 9.80 | 10.58 | 11.98 |
Forward PE | 6.73 | 7.25 | 8.30 | 9.10 | 9.93 | 10.40 |
PS Ratio | 2.31 | 2.43 | 2.67 | 3.06 | 3.34 | 3.77 |
PB Ratio | 1.28 | 1.32 | 1.49 | 1.61 | 1.83 | 2.10 |
P/TBV Ratio | 1.28 | 1.32 | 1.49 | 1.61 | 1.83 | 2.10 |
P/FCF Ratio | 13.80 | 16.65 | 13.03 | 32.71 | 28.71 | 26.61 |
P/OCF Ratio | 8.65 | 10.70 | 10.09 | 21.76 | 14.92 | 17.40 |
PEG Ratio | - | 0.68 | 0.68 | 0.70 | 0.71 | 0.69 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
EV/Sales Ratio | 1.44 | 1.65 | 1.87 | 2.19 | 2.46 | 2.90 |
EV/EBITDA Ratio | 4.52 | 5.84 | 6.45 | 7.00 | 7.57 | 8.58 |
EV/EBIT Ratio | 4.92 | 6.50 | 7.28 | 7.97 | 8.39 | 9.64 |
EV/FCF Ratio | 8.63 | 11.34 | 9.12 | 23.39 | 21.14 | 20.51 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Debt / Equity Ratio | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.00 |
Debt / EBITDA Ratio | 0.01 | 0.04 | 0.07 | 0.10 | 0.10 | 0.01 |
Debt / FCF Ratio | 0.03 | 0.07 | 0.10 | 0.35 | 0.29 | 0.01 |
Net Debt / Equity Ratio | -0.48 | -0.46 | -0.48 | -0.46 | -0.49 | -0.53 |
Net Debt / EBITDA Ratio | -3.01 | -2.99 | -2.95 | -2.77 | -2.75 | -2.79 |
Net Debt / FCF Ratio | -5.17 | -5.81 | -4.17 | -9.27 | -7.68 | -6.67 |
Asset Turnover | 0.56 | 0.55 | 0.55 | 0.52 | 0.56 | 0.57 |
Inventory Turnover | 3.19 | 3.15 | 3.03 | 3.18 | 3.72 | 3.94 |
Quick Ratio | 11.26 | 10.22 | 10.70 | 13.29 | 14.30 | 14.56 |
Current Ratio | 13.78 | 12.80 | 13.48 | 16.67 | 17.03 | 17.33 |
Return on Equity (ROE) | 18.14% | 18.03% | 17.36% | 17.22% | 18.52% | 18.96% |
Return on Assets (ROA) | 9.10% | 8.67% | 8.83% | 8.93% | 10.17% | 10.77% |
Return on Invested Capital (ROIC) | 20.48% | 20.02% | 20.86% | 21.41% | 25.42% | 26.40% |
Return on Capital Employed (ROCE) | 14.40% | 13.80% | 14.10% | 14.20% | 15.60% | 16.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Earnings Yield | 13.41% | 12.94% | 11.19% | 10.21% | 9.45% | 8.35% |
FCF Yield | 7.25% | 6.01% | 7.67% | 3.06% | 3.48% | 3.76% |
Dividend Yield | 5.51% | 6.09% | 5.82% | 5.87% | 5.68% | 3.52% |
Payout Ratio | 40.97% | 40.51% | 44.32% | 46.38% | 29.20% | 24.60% |
Total Shareholder Return | 5.51% | 6.09% | 5.82% | 5.87% | 5.68% | 3.52% |